BC Extra | May 16, 2019
Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
BioCentury | Jan 14, 2017
Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd. ’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead...
BC Week In Review | Jun 27, 2016
Clinical News

AP32788: Phase I/II started

Ariad began an open-label, U.S. Phase I/II trial of oral AP32788 in about 105 NSCLC patients who are refractory to standard available therapies. The dose-escalation Phase I portion will enroll about 20-30 patients and the...
BioCentury | May 23, 2016
Strategy

Continental appetite

Having cut its teeth on the successful U.S. launch of Jakafi ruxolitinib, Incyte Corp. now has global aspirations for the rest of its pipeline. The acquisition of Ariad Pharmaceuticals Inc .'s European commercial business is...
Items per page:
1 - 4 of 4